OBO of CTRS backed by Merieux Equity Partners

Sector(s)
Healthcare
Deal type
Buyout / MBO
Date
December 2020
Countries involved
France

Client

CTRS is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs

Deal

Capitalmind has advised CTRS shareholders on an OBO backed by Mérieux Equity Partners

Parties

Lead team

  • Kilian de Gourcuff

    Kilian de Gourcuff

    Partner France

About the deal

Founded in 2002, CTRS (Cell Therapies Research & Services laboratory) is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs, with a particular focus on orphan diseases. The company can count on approx. 20 employees and generated €15.7 M in 2019.

Mérieux Equity Partners is a global investment platform specialized in the healthcare & nutrition sector, working alongside entrepreneurs and companies with ambitious growth plan, offering them privileged access to sector-expertise and industrial network.

Merieux Equity Partners invested in laboratoires CTRS alongside the management team, via its Merieux Participations 3 vehicle.

What we did

Capitalmind has advised CTRS shareholders all along the OBO process: designing the transaction strategy, building a relevant qualified list of PE funds and organization of a competitive process, management of the debt financing process, marketing of the deal, execution and negotiation up to closing.